Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 5/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 7/20 | 0.40 |
| ▸ | CASP7 | P55210 | 7/20 | 0.40 |
| ▸ | CASP9 | P55211 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | CASP4 | P49662 | 2/20 | 0.38 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.38 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23133189 | 1.00 | CASP1 (0.49) | CASP1OPRD1CASP3CASP7CASP9 | |
| SCHEMBL23133187 | 1.00 | CASP1 (0.49) | CASP1OPRD1CASP3CASP7CASP9 | |
| SCHEMBL20257122 | 1.00 | CASP1 (0.49) | CASP1OPRD1CASP3CASP7CASP9 | |
| SCHEMBL2556937 | 0.92 | CASP1 (0.47) | CASP1CASP3 | |
| SCHEMBL7286925 | 0.92 | CASP1 (0.47) | CASP1CASP3 | |
| SCHEMBL5085996 | 0.92 | CASP1 (0.47) | CASP1CASP3 | |
| SCHEMBL2556934 | 0.92 | CASP1 (0.47) | CASP1CASP3 | |
| SCHEMBL4100803 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP7CASP9BACE1 | |
| SCHEMBL29310042 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP7CASP9BACE1 | |
| SCHEMBL13194679 | 0.87 | CASP1 (0.50) | CASP1CASP3CASP7CASP9BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646425-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2025-11-12 | — | — | EP | disclosed |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | disclosed |
| US-20250188123-A1 | PROTEASE INHIBITORS | UNIVERSITAT REGENSBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| EP-4458846-A2 | NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | Centre National de la Recherche Scientifique (CNRS) (FR) | 2024-11-06 | — | — | EP | disclosed |
| EP-3688019-B1 | NOVEL COMPOUNDS AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | CENTRE NAT RECH SCIENT (FR) | 2024-10-16 | — | — | EP | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| CN-111741970-B | Novel compounds and their use as selective inhibitors of caspase-2 | 法国国家科研中心 | 2024-09-27 | — | — | CN | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| US-11407741-B2 | Compounds and their use as selective inhibitors of caspase-2 | Universite De Paris (FR) | 2022-08-09 | — | — | US | disclosed |
| EP-4005583-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | Industry - University Cooperation Foundation Hanyang University (KR) | 2022-06-01 | — | — | EP | disclosed |
| US-20220160888-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2022-05-26 | — | — | US | disclosed |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-05-18 | — | — | US | disclosed |
| US-10976306-B2 | Protein degradation inducing tag and usage thereof | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2019-10-17 | — | — | US | disclosed |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10976306-B2 | Protein degradation inducing tag and usage thereof | SENP8, SENP6, SENP7 | CASP1 1744/4885OPRD1 4450/4885CASP3 2987/4885 |
| US-20190314508-A1 | P53 DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | TP53, TP53BP1, MDM2 | CASP1 919/4885OPRD1 4394/4885CASP3 626/4885 |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885OPRD1 4792/4885CASP3 1797/4885 |
| US-11052154-B2 | Ras protein degradation inducing molecule and pharmaceutical composition | KRAS, G3BP1, NRAS | CASP1 2718/4885OPRD1 3781/4885CASP3 3966/4885 |
| US-20180164289-A1 | PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF | SENP8, SENP6, SENP7 | CASP1 1744/4885OPRD1 4450/4885CASP3 2987/4885 |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | CASP2, CASP1, CASP3 | CASP1 2/4885OPRD1 4591/4885CASP3 3/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885OPRD1 4792/4885CASP3 1797/4885 |
| US-20220160888-A1 | CP2C-TARGETING PEPTIDE-BASED ANTICANCER AGENT | SREBF2, BCLAF1, CIP2A | CASP1 370/4885OPRD1 4157/4885CASP3 120/4885 |
| US-11007269-B2 | P53 degradation inducing molecule and pharmaceutical composition | TP53, TP53BP1, MDM2 | CASP1 919/4885OPRD1 4394/4885CASP3 626/4885 |
| US-11407741-B2 | Compounds and their use as selective inhibitors of caspase-2 | CASP2, CASP1, CASP3 | CASP1 2/4885OPRD1 4446/4885CASP3 3/4885 |
| US-20250188123-A1 | PROTEASE INHIBITORS | SPINT2, CASP2, CTSZ | CASP1 4/4885OPRD1 4545/4885CASP3 13/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885OPRD1 4792/4885CASP3 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.